Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results


1.		A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Natural history/Epidemiology, Treatment				Active				16 and over				Pharmaceutical / Industry				CA184-025 NCT00162123


2.		Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CA184-029 EORTC 18071, NCT00636168


3.		Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				MDX010-21 NCT00323882

Last Modified: 12/8/2008 First Published: 10/1/2002


4.		Phase II Pilot Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-CTLA4) in Patients With Follicular or Mantle Cell Lymphoma, Colon Cancer, Prostate Cancer Refractory to Vaccine Therapy (Prostate cancer and mantle cell lymphoma closed to accrual as of 3/10/2005; colon cancer closed to accrual as of 9/28/05),Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				NCI-02-C-0284 NCI-5744, NCT00047164, 5744

Last Modified: 11/16/2008 First Published: 5/28/2004


5.		Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Peptide Vaccine Comprising Tyrosinase, gp100 Antigen, and MART-1 Antigen Emulsified in Montanide ISA-51 in Patients With Resected Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				MCC-15241 MDX-010-16, NCI-6446, 6446, NCT00084656, LAC-USC-10M036


6.		MDX-010 for Advanced Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				1564-02 DAMD17-02-1-0245, NCT00170157


7.		Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CA184-041 NCT00527735


8.		Study of Ipilimumab to Treat Melanoma in Patients With Brain Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				Pharmaceutical / Industry				CA184-042 NCT00623766

Last Modified: 11/13/2008 First Published: 6/23/2003


9.		Phase I Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Sargramostim (GM-CSF) in Patients With Metastatic Androgen-Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				UCSF-02558 NCI-6032, NCT00064129, 6032


10.		Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CA184-027 NCT00362713

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute